Dr Eroglu on Addressing Unmet Needs in Mutant Melanoma

Zeynep Eroglu, MD, discusses a phase 1/2 trial that evaluated ceritinib alone and in combination with trametinib in patients with mutant melanoma.

Related Keywords

Zeynep Eroglu ,Moffitt Cancer Center ,Department Of Oncologic Sciences ,Department Of Cutaneous Oncology ,Cutaneous Oncology ,Oncologic Sciences ,South Florida Morsani College ,Melanoma Amp Skin Cancer ,Onclive Tv ,